危重患儿的疾病与死亡:病理生理机制与潜在治疗解决方案
该研究为协作儿科危重症研究网络8个中心参与的多中心结构化病历回顾,由儿科重症医师对2011年12月至2013年4月首次入住PICU、出院时存在显著新发疾病或死亡的患儿进行评审。从681例中随机选取292例,中位年龄2.4岁,233例(79.8%)在内外科ICU、59例(20.2%)在心脏ICU,65例(22.3%)为外科入院,结局包括117例死亡和175例显著新发疾病。最常见的病理生理为底物输送受损(n=158,54.1%)和炎症(n=104,35.6%),各病理生理之间无强相关、无显著聚集。最常见治疗需求为新药(n=149,51.0%)、细胞再生(n=115,39.4%)和免疫炎症调节(n=79,27.1%),同样缺乏强相关或有意义聚集。结论认为不存在单一主导的病理生理或病理生理聚集,治疗需求常涉及尚未临近应用的疗法。
要点
- 292例危重患儿中底物输送受损最常见(n=158,54.1%),其次为炎症(n=104,35.6%),各病理生理间无强相关、无显著聚集。
- 最常需要的治疗为新药(n=149,51.0%)、细胞再生(n=115,39.4%)、免疫炎症调节(n=79,27.1%),治疗需求间同样无强相关或有意义聚集。
- 队列包括117例死亡和175例显著新发疾病,233例(79.8%)来自内外科ICU、59例(20.2%)来自心脏ICU。
- 结论认为不存在单一主导的病理生理或病理生理聚集,治疗需求常涉及细胞再生、改进器官移植、改进体外支持和人工器官、改进药物等尚未临近应用的疗法。
- 该研究为结构化病历回顾,无干预措施,其结论不能直接转化为床旁治疗推荐。
适用人群与场景
- 2011年12月至2013年4月首次入住PICU、出院时存在显著新发疾病或死亡的患儿,来自协作儿科危重症研究网络的8个中心(综合ICU和心脏ICU)。
- 从681例符合条件的患儿中随机选取292例进行结构化病历回顾。
- 233例(79.8%)在内外科ICU,59例(20.2%)在心脏ICU;65例(22.3%)为外科入院。
研究设计与关键结果
- 研究设计:多中心(8个中心)结构化病历回顾,由儿科重症医师评审,无干预措施。
- 研究对象:从681例出院时存在显著新发疾病或死亡的患儿中随机选取292例,中位年龄2.4岁。
- 结局:117例死亡,175例显著新发疾病。
- 主要发现:最常见的病理生理为底物输送受损(n=158,54.1%)和炎症(n=104,35.6%),各病理生理之间无强相关、无显著聚集。
- 治疗需求:新药(n=149,51.0%)、细胞再生(n=115,39.4%)、免疫炎症调节(n=79,27.1%),治疗需求间同样无强相关或无意义聚集。
证据类型、等级与局限
- 证据类型:多中心结构化病历回顾(协作儿科危重症研究网络,8个中心)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究提示危重患儿不良结局的病理生理和治疗需求高度分散,不存在单一主导机制或聚集,床旁不宜按单一病理生理通路制定统一治疗策略。
- 作者认为治疗需求常涉及细胞再生、改进器官移植、改进体外支持和人工器官、改进药物等尚未临近应用的疗法,原文未据此给出床旁推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Developing effective therapies to reduce morbidity and mortality requires knowing the responsible pathophysiologies and the therapeutic advances that are likely to be impactful. Our objective was to determine at the individual patient level the important pathophysiological processes and needed therapeutic additions and advances that could prevent or ameliorate morbidities and mortalities.
DESIGN: Structured chart review by pediatric intensivists of PICU children discharged with significant new morbidity or mortality to determine the pathophysiologies responsible for poor outcomes and needed therapeutic advances.
SETTING: Multicenter study (eight sites) from the Collaborative Pediatric Critical Care Research Network of general and cardiac PICUs.
PATIENTS: First PICU admission of patients from December 2011 to April 2013.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Two-hundred ninety-two patients were randomly selected from 681 patients discharged with significant new morbidity or mortality. The median age was 2.4 years, 233 (79.8%) were in medical/surgical ICUs, 59 (20.2%) were in cardiac ICUs. Sixty-five (22.3%) were surgical admissions. The outcomes included 117 deaths and 175 significant new morbidities. The most common pathophysiologies contributing to the poor outcomes were impaired substrate delivery (n = 158, 54.1%) and inflammation (n = 104, 35.6%). There were no strong correlations between the pathophysiologies and no remarkable clusters among them. The most common therapeutic needs involved new drugs (n = 149, 51.0%), cell regeneration (n = 115, 39.4%), and immune and inflammatory modulation (n = 79, 27.1%). As with the pathophysiologies, there was a lack of strong correlations or meaningful clusters in the suggested therapeutic needs.
CONCLUSIONS: There was no single dominant pathophysiology or cluster of pathophysiologies responsible for poor pediatric critical care outcomes. Therapeutic needs often involved therapies that are not close to implementation such as cell regeneration, improved organ transplant, improved extracorporeal support and artificial organs, and improved drugs.
参考来源
- Pollack MM, Banks R, Holubkov R, et al. Morbidity and Mortality in Critically Ill Children. I. Pathophysiologies and Potential Therapeutic Solutions. Crit Care Med. 2020. PMID: 32301842. doi:10.1097/CCM.0000000000004331
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。